Other Income

6 Months Ended

Jun. 30, 2012

8. Other Income

Other income of $900,000 in the six months ended June 30, 2011 included $251,000 received from the federal government related to the Therapeutic Discovery Tax Credit pursuant to grants received under the Patient Protection and Affordable Care Act of 2010 and $649,000 received pursuant to a business interruption insurance claim the Company made in 2010. The Company will not receive any additional funds related to the Therapeutic Discovery Tax Credit or the business interruption insurance claim. Other income of $678,000 in the six months ended June 30, 2012 includes $66,000 in proceeds from the sale of prototype equipment previously expensed as research and development expense, and $520,000 related to the purchase agreement with Sequenom and $92,000 from the settlement agreement with Pacific Biosciences. Other income amounts related to Sequenom and Pacific Biosciences are net of the amounts the Company owes to its lenders, ligation counsel and licensors. As of the date of this filing, the Purchasers have not made a demand for payment of the amount due under the Risk Premium Agreement associated with this transaction.

HELICOS BIOSCIENCES CORP 10-Q